David Rafei‐Shamsabadi

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Markus V. Heppt, Lucie Heinzerling, Katharina C. Kähler et al. · European Journal of Cancer · 2017 · 196 citations

Prognostic Factors, Programmed Cell Death-1, Medicine +9

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients

Teresa Amaral, Felix Kiecker, Sarah Schaefer et al. · Journal for ImmunoTherapy of Cancer · 2020 · 86 citations · Full text

MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors

Dominik Marschner, Martina Falk, Nóra Rebeka Jávorniczky et al. · JCI Insight · 2020 · 81 citations · Full text

Diagnostics in Hymenoptera venom allergy: current concepts and developments with special focus on molecular allergy diagnostics

Thilo Jakob, David Rafei‐Shamsabadi, Edzard Spillner et al. · Allergo Journal International · 2017 · 73 citations · Full text

Allergy, Molecular Allergy Diagnostics, Allergy Medicine +9

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Jürgen C. Becker, Selma Ugurel, Ulrike Leiter et al. · The Lancet · 2023 · 63 citations

Tumor Immunology, Surgical Oncology, Nivolumab Versus Observation +10